[go: up one dir, main page]

BRPI0116013B8 - composição farmacêutica para potenciar a imunogenicidade de antígenos pouco imunogênicos, e, uso da composição farmacêutica - Google Patents

composição farmacêutica para potenciar a imunogenicidade de antígenos pouco imunogênicos, e, uso da composição farmacêutica

Info

Publication number
BRPI0116013B8
BRPI0116013B8 BRPI0116013A BRPI0116013B8 BR PI0116013 B8 BRPI0116013 B8 BR PI0116013B8 BR PI0116013 A BRPI0116013 A BR PI0116013A BR PI0116013 B8 BRPI0116013 B8 BR PI0116013B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
immunogenicity
enhance
proteoliposomes
poorly immunogenic
Prior art date
Application number
Other languages
English (en)
Inventor
De La Barrera Aira Anabel
Sanchez Ramirez Belinda
Mesa Pardillo Circe
Raul Suarez Pestana Eduardo
De Leon Delgado Joel
Enrique Fernandez Molina Luis
Perez Rodriguez Rolando
Diaz Rodriguez Yildian
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CU20000285A external-priority patent/CU23000A1/es
Priority claimed from CU20010167A external-priority patent/CU23009A1/es
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Publication of BR0116013A publication Critical patent/BR0116013A/pt
Publication of BRPI0116013B1 publication Critical patent/BRPI0116013B1/pt
Publication of BRPI0116013B8 publication Critical patent/BRPI0116013B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"composição farmacêutica para potenciar a imunogenicidade de antígenos pouco imunogênicos, e, usos da mesma e de proteolipossomas". a presente invenção refere-se à imunologia e, mais especificamente, a composições imunogênicas que contêm peptídeos, polipeptídeos, proteínas, suas correspondentes seqüências de dna, células ou seus lisados e proteoliposomas de tamanho muito pequeno (vssp), sendo que estes últimos são formados ao se ligar o complexo de proteínas da membrana externa (cpme) de neisseria meningitidis com gangliosídeos, através de ligações hidrofóbicas. em particular, esta invenção mostra como preparar composições imunoestimuladoras capazes de gerar respostas imunes específicas-para-antígeno, inclusive em hospedeiros imunocomprometidos, como são os que padecem de câncer e de infecções de origem viral ou bacteriana crônicas. nestes pacientes, a administração das composições de vacina descritas permite restaurar a funcionalidade de setores de seu sistema imunológico. as composições de vacina desta invenção podem ser utilizadas para proteger de, ou tratar, doenças infecciosas, malignas ou autoimunes.
BR0116013-3 2000-12-06 2001-12-06 composição farmacêutica para potenciar a imunogenicidade de antígenos pouco imunogênicos, e, uso da composição farmacêutica BRPI0116013B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CU20000285A CU23000A1 (es) 2000-12-06 2000-12-06 Composiciones vacunales para la inmunoterapia activa específica del cáncer
CU285/2000 2000-12-06
CU167/2001 2001-07-12
CU20010167A CU23009A1 (es) 2001-07-12 2001-07-12 Preparaciones para potenciar la inmunogenicidad depreparaciones para potenciar la inmunogenicidad de antígenos poco inmunogénicos antígenos poco inmunogénicos
PCT/CU2001/000010 WO2002045746A2 (es) 2000-12-06 2001-12-06 Composiciones farmaceuticas para potenciar la inmunogenicidad de antigenos poco inmunogenicos

Publications (3)

Publication Number Publication Date
BR0116013A BR0116013A (pt) 2004-01-06
BRPI0116013B1 BRPI0116013B1 (pt) 2018-07-24
BRPI0116013B8 true BRPI0116013B8 (pt) 2021-05-25

Family

ID=38812545

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116013-3 BRPI0116013B8 (pt) 2000-12-06 2001-12-06 composição farmacêutica para potenciar a imunogenicidade de antígenos pouco imunogênicos, e, uso da composição farmacêutica

Country Status (19)

Country Link
US (1) US7776342B2 (pt)
EP (1) EP1356822B1 (pt)
JP (1) JP4210519B2 (pt)
KR (1) KR100850473B1 (pt)
CN (1) CN1291755C (pt)
AR (1) AR031638A1 (pt)
AT (1) ATE485833T1 (pt)
AU (2) AU2151902A (pt)
BR (1) BRPI0116013B8 (pt)
CA (1) CA2431188C (pt)
DE (1) DE60143363D1 (pt)
DK (1) DK1356822T3 (pt)
EA (1) EA005138B1 (pt)
MX (1) MXPA03005032A (pt)
NZ (1) NZ526282A (pt)
PE (1) PE20020572A1 (pt)
UY (1) UY27059A1 (pt)
WO (1) WO2002045746A2 (pt)
ZA (1) ZA200304411B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1358910A1 (de) * 2002-05-02 2003-11-05 B.R.A.H.M.S Aktiengesellschaft Verfahren und Mittel zur Prävention, Hemmung und Therapie von Krebserkrankungen
EP1367395A1 (de) * 2002-05-02 2003-12-03 B.R.A.H.M.S Aktiengesellschaft Diagnose von Neoplasmen mit Hilfe von anti-Gangliosid-Antikörpern
CU23257A1 (es) * 2003-02-27 2008-01-24 Centro Inmunologia Molecular COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA
AR045815A1 (es) * 2003-10-09 2005-11-16 Ct Ingenieria Genetica Biotech Composiciones farmaceuticas que contienen antigenos del virus de papiloma humano
WO2005111079A2 (en) * 2004-05-14 2005-11-24 The United States Of America As Represented By The Secretary Department Of Health And Human Services Hiv vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-hiv-1 antibodies against the membrane proximal domain of hiv gp41
US20110189231A1 (en) * 2008-06-17 2011-08-04 Denis Leclerc Compositions Comprising Salmonella Porins and Uses Thereof as Adjuvants and Vaccines
CN103501810A (zh) * 2010-12-22 2014-01-08 拜耳知识产权有限责任公司 牛物种中增强的免疫应答
KR101323845B1 (ko) * 2011-01-21 2013-10-31 광주과학기술원 외막소포체를 유효성분으로 포함하는 항암용 약제학적 조성물
CU24070B1 (es) * 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
WO2014140894A2 (en) * 2013-03-15 2014-09-18 Bioven 3 Limited Self-assembling synthetic proteins
CU24299B1 (es) * 2013-08-02 2017-12-08 Centro De Inmunología Molecular Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico
HK1194912A2 (en) * 2013-09-17 2014-10-24 Bestop Group Holdings Ltd Growth factor concentrate and the use thereof
US10105306B2 (en) * 2013-09-17 2018-10-23 Bestop Group Holdings Limited Method of preparing a growth factor concentrate
JP6609565B2 (ja) * 2014-03-11 2019-11-20 ユニヴェルシテ デクス−マルセイユ 細胞膜ガングリオシドと相互作用するキメラペプチド
US12019073B2 (en) * 2017-03-15 2024-06-25 Centro De Inmunologia Molecular Method for the treatment of patients with carcinomas
WO2018166542A1 (es) 2017-03-15 2018-09-20 Centro De Inmunologia Molecular Método para el tratamiento de pacientes con carcinomas
AU2018341578B2 (en) * 2017-09-27 2024-02-08 L2 Diagnostics, Llc ErbB peptide pharmaceutical and vaccine compositions and therapeutics uses thereof for cancer
CU24534B1 (es) * 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras
CN109865137A (zh) * 2019-01-23 2019-06-11 天德悦（北京）生物科技有限责任公司 经碘代乙酰基活化的琼脂糖微球在提高多肽或蛋白类免疫原免疫原性中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857637A (en) * 1986-05-07 1989-08-15 Genentech, Inc. Methods and compositions for immunologically modulating growth hormone receptor activity
IT1206250B (it) * 1987-02-18 1989-04-14 Ist Farmacoterapico It Spa Stiche umane e relativi prodotti metodo per l'estrazione di antigeni di membrana aventi proprieta' immunogene a partire da cellule neopla-
US5726292A (en) * 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
AU4662393A (en) 1992-07-08 1994-01-31 Schering Corporation Use of gm-csf as a vaccine adjuvant
ES2166770T3 (es) * 1993-12-09 2002-05-01 Centro Inmunologia Molecular Anticuerpos monoclonales contra gangliosidos y sus utilizaciones en la inmunoterapia activa especifica de tumores malignos.
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
EP1045698B1 (en) * 1998-01-16 2006-06-07 Biomira Usa Inc. Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes

Also Published As

Publication number Publication date
MXPA03005032A (es) 2004-09-10
UY27059A1 (es) 2002-04-26
AR031638A1 (es) 2003-09-24
KR20030061838A (ko) 2003-07-22
US7776342B2 (en) 2010-08-17
DE60143363D1 (de) 2010-12-09
ZA200304411B (en) 2004-07-29
WO2002045746A3 (es) 2002-12-27
EA005138B1 (ru) 2004-12-30
KR100850473B1 (ko) 2008-08-07
EA200300640A1 (ru) 2003-12-25
DK1356822T3 (da) 2011-02-07
WO2002045746A2 (es) 2002-06-13
JP2004523494A (ja) 2004-08-05
CN1291755C (zh) 2006-12-27
CA2431188C (en) 2010-09-07
HK1063726A1 (en) 2005-01-14
BRPI0116013B1 (pt) 2018-07-24
AU2002221519B2 (en) 2006-11-23
EP1356822A2 (en) 2003-10-29
BR0116013A (pt) 2004-01-06
PE20020572A1 (es) 2002-07-31
EP1356822B1 (en) 2010-10-27
CA2431188A1 (en) 2002-06-13
JP4210519B2 (ja) 2009-01-21
AU2151902A (en) 2002-06-18
ATE485833T1 (de) 2010-11-15
US20020136735A1 (en) 2002-09-26
CN1484532A (zh) 2004-03-24
NZ526282A (en) 2005-01-28

Similar Documents

Publication Publication Date Title
BRPI0116013B8 (pt) composição farmacêutica para potenciar a imunogenicidade de antígenos pouco imunogênicos, e, uso da composição farmacêutica
US6821521B1 (en) Multicomponent meningococcal vaccine
ES2400531T3 (es) Expansión del repertorio de los linfocitos T para incluir epítopos subdominantes mediante vacunación con antígenos administrados en forma de fragmentos proteicos o cócteles peptídicos
CN101745104B (zh) 含有复合佐剂的结核亚单位疫苗
Golovliov et al. Adjuvanticity of ISCOMs incorporating a T cell-reactive lipoprotein of the facultative intracellular pathogen Francisella tularensis
Alexyuk et al. Adjuvant activity of multimolecular complexes based on Glycyrrhiza glabra saponins, lipids, and influenza virus glycoproteins: PG Alexyuk et al.
BRPI0107679B8 (pt) composição compreendendo vesículas de membrana externa do grupo sérico b de neisseria meningitidis e um componente inorgânico e uso da mesma
WO1998008542A3 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
HUP9901039A2 (hu) Neisseria meningitidis B-csoportba tartozó külső-membrán-fehérjéjének (MB3) expressziója élesztőben, továbbá vakcinák
BR9913446A (pt) Produtos de aglicona e métodos de uso
JP2004523494A5 (pt)
BR112019019117A2 (pt) métodos e composições para induzir respostas imunes contra clostridium difficile
ES2424131T3 (es) Vacuna para modular respuestas inmunitarias entre T1 y T2
AU2016201589B2 (en) Peptide adjuvants
Lövgren-Bengtsson et al. The ISCOM™ technology
ES2387436B1 (es) Vacuna frente a acinetobacter
BRPI0416178A (pt) método de incorporação de antìgeno em vesìculas de membrana externa de bactérias neisseria e formulações de vacina resultantes
Pier Is Pseudomonas aeruginosa exotoxin A a good carrier protein for conjugate vaccines?
Liu Natural and biotech‐derived therapeutic proteins: What is the future?
MY129626A (en) Preparations that potentiate immunogenicity in low immunogenic antigens
Pilapil et al. Programmed Instruction: Cancer Care
Jones et al. Subcellular Location Of MAC-1 (CR-3) In Human Neutrophils: Effects Of Chemotactic Factors And PMA
CU23009A1 (es) Preparaciones para potenciar la inmunogenicidad depreparaciones para potenciar la inmunogenicidad de antígenos poco inmunogénicos antígenos poco inmunogénicos
EP0646377A1 (en) Albumin-conjugated tumour cell-free extracts, antigenic compositions comprising the same, related antibodies, and uses thereof
Giller et al. Immunogenicity of purified varicella zoster virus glycoproteins

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/07/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/12/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 06/12/2021.